强骨宝治疗马来西亚膝骨关节炎患者的疗效观察

发布时间：2018-09-09 11:07

【摘要】：目的：1.分析马来西亚骨关节炎的现状：2.观察强骨宝治疗马来西亚膝骨关节炎患者的临床作用；3.评估强骨宝临床运用的安全性；4.探索强骨宝有效成分的抗氧化作用。方法：将60例入选的膝骨关节炎患者按照要求口服给药,受试者每天服强骨宝颗粒剂(补骨脂15克、骨碎补15克、三七3克、甘草6克)两次,每日1剂,每天服药两次,早、晚饭后半小时各1次,200m1温水冲服,需连续8周。每个受试者治疗期间共需要参加5次随访,分别为就诊后第1天、第2周末、第4周末、第6周末、第8周末。每次随访均记录：心率、心脏收缩压、心脏舒张压、血常规、生化全套、肝功能、肾功能、尿常规；而心电图(ECG)测量则分别在就诊后第1天和第6周末进行。根据患者的临床疗效、VAS评分、膝关节肿胀评分、WOMAC指数、Karnofsky评分进行分析,进行自身前后对照。结果：1.受试者平均年龄为56岁；OA平均发病年龄为53.98岁；平均体重指数(BMI)是23.77 kg/m2；在60例中,其中华人占绝大比例：88.30%;48.30%的受试者的受教育年限为1-6年；71.70%已婚,78.30%是家庭主妇；45%既往无特殊病史；OA症状持续时间多为2年。2.在8周治疗期间,受试者的心率、心脏收缩压、心脏舒张压和心电图仍均保持在正常范围内。3.通过VAS评分标准分析：对比随访1和随访2,统计学无意义(P=0.2890.05),提示患者疼痛无明显减轻；对比随访2和随访3,统计学有意义(P0.05),提示患者疼痛减轻；对比随访3和随访4(P0.05)以及随访4和随访5(P0.05),两者皆具有显著结果及统计学意义,提示该药可减轻患者疼痛。4.通过膝关节肿胀评分标准分析：比较随访1和随访2(P0.05)、随访2和随访3(P0.05),统计学均无意义,提示患者膝关节肿胀无减少；比较随访3和随访4(P0.05)、随访4和随访5(P0.05),统计学意义均有意义,提示患者膝关节的肿胀减少。5.通过WOMAC骨关节炎指数综合评分标准分析：对比随访1和随访2、随访2和随访3、随访3和随访4、随访4和随访5,患者膝关节疼痛、僵硬程度和活动功能(P0.05,P0.05,P0.05),均具有显著统计学意义,提示患者膝关节疼痛及关节僵硬减轻、活动功能改善。6.根据Karnofsky评分分析：对比随访1和随访2,差异无统计学意义(P0.05),提示患者生活质量无明显改善；对比随访2和随访3、随访3和随访4以及随访4和随访5,差异均有统计学意义(P0.05,P0.05,P0.05),提示患者生活质量得到改善。7.DPPH实验分析：强骨宝的平均抗氧化作用为74.1%,提示强骨宝有效成分具有较强的抗氧化作用。结论：强骨宝对膝骨关节炎有一定治疗效果,能有效改善骨关节炎症和功能,缓解疼痛,延缓和控制病情发展,提高患者生活质量,且作用安全,尚无明显不良反应发生。
[Abstract]:Purpose 1. Analysis of the present situation of osteoarthritis in Malaysia: 2. To observe the clinical effect of Qianggu Bao in treating Malaysian knee osteoarthritis. To evaluate the safety of Qianggu Bao in clinical use. To explore the anti-oxidation effect of Qianggubao active ingredient. Methods: 60 patients with osteoarthritis of knee were given orally according to the request. The subjects took Qianggu Bao granule (psoralen 15 g, broken bone 15 g, Sanqi 3 g, licorice 6 g) twice a day, early in the morning. Take 200 m 1 warm water once half an hour after supper for 8 weeks. Each participant was followed up for 5 times during the treatment period, one day after treatment, the second weekend, the fourth weekend, the sixth weekend, and the eighth weekend. Heart rate, systolic blood pressure, diastolic blood pressure, blood routine, biochemical complete set, liver function, renal function and urine routine were recorded at each follow-up, while (ECG) was measured on the 1st day and the 6th week after treatment. According to the clinical curative effect and VAS score, knee joint swelling score and WOMAC index Karnofsky score were analyzed and compared. The result is 1: 1. The average age of onset of OA was 53.98 years old, the average body mass index (BMI) was 23.77 kg/m2; in 60 cases, Chinese accounted for 48.30% of the subjects, and 71.70% of the subjects were married housewives for 1-6 years. The average age of onset of OA was 53.98 years, and the average body mass index (BMI) was 23.77 kg/m2; in 60 cases, and the Chinese accounted for 48.30% of the subjects, and 71.70% of the subjects were housewives. The duration of OA symptoms in 45% patients without special history was 2 years. Heart rate, systolic blood pressure, diastolic blood pressure and electrocardiogram remained within normal range. According to the analysis of VAS score: there was no significant difference between follow-up 1 and follow up 2 (P < 0. 2890.05), which indicated that the pain of the patients was not alleviated, compared with follow-up 2 and follow up 3, there was statistical significance (P0.05), suggesting that the pain of the patients was alleviated. Compared with follow-up 3 and 4 (P0.05) and follow-up 4 and 5 (P0.05), both showed significant results and statistical significance, suggesting that the drug can alleviate pain. 4. According to the analysis of knee joint swelling score: 1 and 2 (P0.05), 2 (P0.05), 2 (P0.05), 2 (P0.05), 2 (P0.05), 2 (P0.05), 3 (P0.05), 3 (P0.05), 4 (P0.05), 4 (P0.05) and 5 (P0.05), respectively, were statistically significant. It suggested that the swelling of knee joint was decreased. According to the comprehensive score of WOMAC osteoarthritis index: compared with 1 and 2 follow-up, 2 and 3 follow-up, 3 and 4 follow-up, 4 and 5 follow-up, the knee joint pain, stiffness and activity function (P0. 05 and P0. 05) were statistically significant. It suggested that the knee joint pain and joint stiffness were alleviated, and the motor function was improved by .6. According to Karnofsky score analysis, there was no significant difference between follow-up 1 and follow-up 2 (P0.05), suggesting that the quality of life of the patients did not improve significantly. There was significant difference between follow-up 2 and 3, follow up 3 and follow up 4 and follow up 5. The difference was statistically significant (P0.05, P0.05, P0.05), indicating that the quality of life of patients was improved .7.DPPH experimental analysis: the average antioxidant activity of Qianggu Bao was 74.1% and that of Qianggu Bao was 74.1%. The active component of Bao has strong antioxidation effect. Conclusion: Qianggu Bao has a certain therapeutic effect on knee osteoarthritis, which can effectively improve the inflammation and function of osteoarthritis, relieve pain, delay and control the development of the disease, improve the quality of life of the patients, and the effect is safe, and there is no obvious adverse reaction.
【学位授予单位】：福建中医药大学
【学位级别】：博士
【学位授予年份】：2016
【分类号】：R274.9

【相似文献】